Recently, intravitreal injections of anti-VEGF agents are commonly used for several retinal diseases, e.g. retinal vein occlusion, age-related macular degeneration, and others, and a transient increase in IOP is a well-known complication of intravitreal injections of anti-VEGF agents9–11. The gene discussed is VEGFA; the disease is retinal vein occlusion.